-transparent.png){kind=logo}
A low-dose maintenance schedule of adriamycin was evaluated in children with advanced acute lymphoblastic leukemia. Thirty-six evaluable patients who achieved two or more remissions were given adriamycin, 10 mg/m2/week, as a single maintenance agent. The median duration of second remission was 17 weeks, but only 5 weeks for third and fourth remission. Although the therapy was not found effective in more advanced disease, the median duration of second remission approached that obtained from various multi-agent treatment schedules. We conclude that the therapeutic efficacy of this treatment schedule makes it appealing for incorporation into multi-drug combination regimens.
Related Publications
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
January 1977,
Medical and pediatric oncology,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
January 1975,
Medical and pediatric oncology,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
October 1975,
Cancer,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
March 1982,
Cancer,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
August 1979,
Cancer treatment reports,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
January 1980,
Cancer treatment reports,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
August 2000,
Leukemia,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
October 1991,
Seminars in oncology,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
January 1978,
Medical and pediatric oncology,
E Hvizdala, and
D Komp, and
A Ragab, and
W Crist, and
J Y Chu
September 1982,
Cancer,
